

02/02/01
JC891 U.S. PRO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING NATIONAL PATENT APPLICATION

Under 35 USC 111(a) and Rule 53(b)

PATENT APPLICATION

Hon. Commissioner of Patents
Washington, D.C. 20231

WITH SIGNED DECLARATION

NONPROVISIONAL
NON REISSUE
NON PCT NAT PHASE



00909

11011 U.S. PRO
09/773599
02/02/01

Sir:

Herewith is the PATENT APPLICATION of
Inventor(s): SMITH, John Craig

Title DIAGNOSTIC METHOD

Atty. Dkt.: P 276655 PHM70655/US
M# Client Ref

including:

Date: February 2, 2001

1. Specification: 32 pages (only spec. and claims) 2. ☐ Specification in non-English language
3. Declaration ☒ Original ☐ Facsimile/Copy ☒ Abstract 1 page(s); 22 numbered claims
4. ☐ Drawings: sheet(s) ☐ informal; ☐ formal of size: ☐ A4 ☐ 11"
5. ☐ See top first page re prior Provisional, National or International application(s). ("X" box only if info is there and do not complete corresponding item 5 or 6). (Prior M# SN)
6. **AMEND the specification** please by inserting before the first line: -- This is a ☐ Continuation-in-Part
☐ Divisional ☐ Continuation ☐ Substitute Application (MPEP 201.09) of:
- 6(a) ☐ National Appln. No. / filed (M#)
- 6(b) ☐ International Appln. No. filed
which designated the U.S., and that International Application ☐ was ☐ was not published under PCT Article 21(2) in English.--
7. ☐ **AMEND the specification** by inserting before the first line: -- This application claims the benefit of U.S. Provisional Application No. 60/ , filed . --
8. ☒ Attached is an assignment and cover sheet. Please return the recorded assignment to the undersigned.
9. ☐ Prior application is assigned to

by Assignment recorded Reel Frame

10. **FOREIGN** priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in GREAT BRITAIN

11. (country)

| Application No. | Filing Date | Application No. | Filing Date |
|-----------------|------------------|---|-------------|
| (1) 0002366.3 | February 3, 2000 | (2) | |
| (3) | | (4) | |
| (5) | | (6) | |
| (7) | | (8) | |
| (9) | | <input type="checkbox"/> See 3 rd page for additional priorities | |

12. 1 (No.) Certified copy (copies): ☒ attached; ☐ previously filed (date)
in U.S. Application No. / filed on
13. Small entity status ☐ ☒ is **not** claimed; ☐ is claimed (Pre-filing confirmation required)
- 13(a). ☐ Attached: (No.) Small Entity Statement(s) (since 9/8/00 small entity statement(s) not essential to make claim)

14. DOMESTIC/INTERNATIONAL priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

| Application No. | Filing Date | Application No. | Filing Date |
|-----------------|-------------|-----------------|-------------|
| (1) | | (4) | |
| (2) | | (5) | |
| (3) | | (6) | |

15. ☐ This application is being filed under Rule 53(b)(2) since an inventor is named in the enclosed Declaration who was not named in the prior application.

16. ☒ Attached: 6 Pages of Sequence Listing

17. ☐ Preliminary Amendment:

THE FOLLOWING FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY ABOVE CANCELLED

| | | | | Large/Small Entity | | Fee Code |
|--|----|------------|-----|--------------------|--------|----------|
| 18. Basic Filing Fee | | | | \$710/\$355 | \$710 | 101/201 |
| 19. Total Effective Claims | 27 | minus 20 = | *7 | x \$18/\$9 = | + 126 | 103/203 |
| 20. Independent Claims | 14 | minus 3 = | *11 | x \$80/\$40 = | + 880 | 102/202 |
| *If answer is zero or less, enter "0" | | | | | | |
| 21. If any proper multiple dependent claim (ignore improper) is present, add (Leave this line blank if this is a reissue application) | | | | + \$270/\$135 | + 270 | 104/204 |
| 22. TOTAL FILING FEE ENCLOSED = | | | | | \$1986 | |
| 23. If "non-English" box 2 is X'd, add Rule 17(k) processing fee | | | | + \$130 | + 0 | 139 |
| 24. If "assignment" box 8 is X'd, add recording fee | | | | + \$40 | + 40 | 581 |
| 25. <input type="checkbox"/> Attached is a Petition/Fee under Rule No. | | | | + \$130 | + 0 | 122 |
| 26. TOTAL FEE ENCLOSED = | | | | | \$2026 | |

Our Deposit Account No. 03-3975

Our Order No. 9901

C#

276655

M#



00909

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

**Pillsbury Winthrop LLP
Intellectual Property Group**

By Atty: Donald J. Bird

Reg. No. 25323

Sig:

Fax: (202) 822-0944

Tel: (202) 861-3027

Atty/Sec: DJB/mhn

NOTE: File in duplicate with 2 post card receipts (PAT-103) & attachments

APPLICATION UNDER UNITED STATES PATENT LAWS

Atty. Dkt. No. PM 276655/PHM 70655/US
(M#)

Invention: DIAGNOSTIC METHOD

Inventor (s): SMITH, John Craig

Pillsbury Winthrop LLP
Intellectual Property Group
1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Attorneys
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☒ Regular Utility Application
- ☐ Continuing Application
 - ☒ The contents of the parent are incorporated by reference
- ☐ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification
 - Sub. Spec Filed _____
 - in App. No. _____ / _____
- ☐ Marked up Specification re
 - Sub. Spec. filed _____
 - In App. No _____ / _____

SPECIFICATION

SUBSTANTIVE SPECIFICATION

AstraZeneca Case No. Z70655 / OS

Specification for use in: USA

Claiming priority from UK Patent

Application No. 0002366.3

Filed on 03 February 2000

Inventors:

SMITH; John Craig

**a British citizen and Research Scientist
of Alderley Park, Macclesfield,
Cheshire.**

GB. SK10 4TG.

TITLE:

DIAGNOSTIC METHOD

APPLICANT:

AstraZeneca AB,
S-151 85 Södertälje, Sweden.

0002366.3